Fujiwara, K., Chou, H., Kim, J., Tan, D. S., Tamura, K., Katsumata, N., Harano, K., Hasegawa, K., Hume, S., Jones, E., Goble, S., Sullivan, L., Shih, D., Coleman, R. L., McNeish, I., Monk, B., & Kristeleit, R. (n.d.). 263TiPATHENA (GOG-3020/ENGOT-ov45): A randomised, double-blind, placebo-controlled phase III study of the poly (ADP-ribose) polymerase (PARP) inhibitor rucaparib + the PD-1 inhibitor nivolumab following frontline platinum-based chemotherapy in ovarian cancer. Annals of oncology, 30, . http://access.bl.uk/ark:/81055/vdc_100098039900.0x00003c